source
- Cerevance reports positive Phase 3 results for Parkinson’s drug solengeprasCerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…
- EMA to revise pharmacogenomics guideline as MHRA adopts AI framework for medical devicesThe European Medicines Agency’s Committee for Medicinal Products for Human Use is preparing a major revision of its 2018 guideline on good pharmacogenomic practices. Regulators say the rapid advan…